Keyphrases
Meta-analysis
100%
Systematic Meta-analysis
97%
Confidence Interval
60%
Relative Risk
39%
Randomized Controlled Trial
23%
Retrospective Cohort Study
22%
Meta-analysis of Randomized Controlled Trials
22%
All-cause Mortality
20%
Risk Ratio
20%
Adverse Events
19%
Overall Survival
19%
Chemotherapy
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
18%
Hazard Ratio
17%
Cancer Patients
16%
Positron Emission Tomography-computed Tomography (PET-CT)
16%
Venous Thromboembolism
13%
Anemia
13%
Intravenous Iron
12%
Follicular Lymphoma
12%
Acute Myeloid Leukemia
12%
Hematological Malignancies
12%
Rituximab
11%
Adult Patients
11%
Oncology Patients
11%
Bacterial Infection
11%
Chronic Myeloid Leukemia
10%
Randomized Trial
10%
Infection Rate
10%
Hemoglobin
10%
Placebo
10%
Antibiotics
10%
Maintenance Therapy
9%
Thrombocytopenia
9%
Hospitalization
9%
Tyrosine Kinase Inhibitor
9%
Bendamustine
9%
Fever of Unknown Origin
9%
Infectious Complications
8%
Patients with Hematological Malignancies
8%
Sepsis
8%
Odds Ratio
8%
Neutropenic Patients
8%
Community-acquired Pneumonia
8%
Diffuse Large B-cell Lymphoma (DLBCL)
8%
Neutropenia
7%
Hemoglobin Level
7%
Israel
7%
Progression-free Survival
7%
Risk Factors
7%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
54%
Randomized Controlled Trial
41%
Cohort Study
27%
Adverse Event
25%
Malignant Neoplasm
23%
Chemotherapy
22%
All Cause Mortality
20%
Overall Survival
20%
Venous Thromboembolism
20%
Disease
18%
Anemia
17%
Hematologic Malignancy
17%
Rituximab
17%
Antibiotics
13%
Placebo
11%
Bacterial Infection
11%
Acute Myeloid Leukemia
10%
Follicular Lymphoma
10%
Neutropenia
9%
Thrombocytopenia
9%
Bendamustine
9%
Remission
9%
Sepsis
8%
Community Acquired Pneumonia
8%
Retrospective Study
8%
Ceftriaxone
7%
Myelodysplastic Syndrome
7%
Chronic Lymphatic Leukemia
7%
Diffuse Large B Cell Lymphoma
7%
Bleeding
7%
Inappropriate Vasopressin Secretion
6%
Chronic Kidney Failure
6%
Iron
6%
Meningococcosis
6%
Antibiotic Prophylaxis
6%
Aplastic Anemia
6%
Infectious Complication
6%
Protein Tyrosine Kinase Inhibitor
6%
Ciclosporin
6%
Rifampicin
6%
Bacteremia
5%
Immunosuppressive Agent
5%
Chronic Myeloid Leukemia
5%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
5%
Quinolone Derivative
5%
Infection Rate
5%
Antibiotic Agent
5%
Azacitidine
5%
Mortality Rate
5%
Multiple Myeloma
5%
Medicine and Dentistry
Meta-Analysis
67%
Systematic Review
58%
Infection
34%
Randomized Controlled Trial
23%
Anemia
19%
Retrospective Cohort Study
17%
Malignant Neoplasm
17%
Positron Emission Tomography-Computed Tomography
16%
Cancer
14%
Overall Survival
13%
Disease
13%
Hematologic Malignancy
13%
Adverse Event
11%
Venous Thromboembolism
11%
All Cause Mortality
11%
Rituximab
9%
Hazard Ratio
9%
Diffuse Large B-Cell Lymphoma
8%
Kidney Graft
8%
Fever of Unknown Origin
8%
Supplementation
8%
Antibiotics
8%
Retrospective Study
8%
Arm
8%
Cell Transplantation
7%
Cohort Analysis
7%
Iron Deficiency
7%
Positron Emission Tomography
7%
Thrombocytopenia
7%
Iron
6%
Sepsis
6%
Neutropenia
6%
Fluorodeoxyglucose F 18
6%
Transplantation
6%
Maintenance Therapy
6%
Diagnosis
6%
Chronic Kidney Disease
6%
Immunosuppressive Treatment
5%
Hematopoietic Stem Cell
5%
Follicular Lymphoma
5%
Anticoagulation
5%
Acute Myeloid Leukemia
5%
Platelet
5%
Progression Free Survival
5%
Febrile Neutropenia
5%
Infectious Complication
5%
Kidney Transplantation
5%
Graft Failure
5%